Shoshana Aronowitz of the School of Nursing, Zack Meisel of the Perelman School of Medicine, and colleagues assessed the various types of prior authorization requirements for Medicaid-covered buprenorphine treatment across the 50 states, which present barriers to evidence-based treatment and overdose prevention.
Bureaucratic burdens for buprenorphine
